Release Date: December 15, 2025
Expiration Date: December 15, 2026
Activity Overview
The treatment of gastroesophageal adenocarcinoma (GEAs) has transformed as novel targeted and immunologic therapies have been characterized. In particular, multiple treatment approaches are now available for management of HER2-positive disease across the treatment continuum for metastatic disease, with new therapeutic options poised to join the therapeutic arsenal.
This podcast features a discussion of current
best practices for the management of HER2-positive advanced or metastatic GEAs,
led by Rohit Gosain, MD; and Rahul Gosain, MD, and featuring a faculty expert
focused on the management of these tumors.
Target Audience
This educational activity is directed toward US and Global community medical oncologists, pathologists, oncology nurses, nurse practitioners, and advanced practice providers who manage patients with GEA.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Review guideline recommendations for biomarker testing in GEA
- Evaluate how HER2 positivity influences treatment decisions in GEA and discuss strategies to address gaps in HER2 testing and therapy access
Rahul Gosain, MD, MBA
Medical Director of Wilmot Cancer Institute at Webster
Director of Wilmot Cancer Institute Regional Infusion Services
Assistant Professor of Clinical Medicine
Wilmot Cancer Institute - University of Rochester
Rochester, NY
Disclosures: Consultancy/Advisory: AstraZeneca, Gilead, Janssen Oncology; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD.
Rohit Gosain, MD
Director of Roswell Park Care Network Southtowns
Assistant Professor of Clinical Medicine
Roswell Park Comprehensive Cancer Center - University at Buffalo
Rochester, NY
Disclosures: Consultancy/Advisory: Eisai; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
Rutika Mehta, MD, MPH
Associate Professor, Division of Hematology/Oncology
Weill Cornell Medicine/New York Presbyterian Hospital
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, Astellas, AstraZeneca, BMS, Daiichi Sankyo, Eli Lilly, Jazz, Legend Biotech, Replimmune; Grant/Research Funding: Robert A Winn CDA
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.